UBS AM
RLMD icon

UBS AM’s Relmada Therapeutics RLMD Stock Holding History

UBS AM’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22,671
Closed -$839K – 2713
2022
Q3 		$839K Buy
22,671
+9,142
+68% +$253K ﹤0.01% 2069
2022
Q2 		$257K Sell
13,529
-10,591
-44% -$231K ﹤0.01% 2514
2022
Q1 		$651K Buy
+24,120
New +$499K ﹤0.01% 2357
2021
Q3 		– Sell
-7,358
Closed -$236K – 2770
2021
Q2 		$236K Buy
7,358
+958
+15% +$33.3K ﹤0.01% 2691
2021
Q1 		$225K Hold
6,400
– – ﹤0.01% 2543
2020
Q4 		$205K Sell
6,400
-5,500
-46% -$189K ﹤0.01% 2495
2020
Q3 		$448K Buy
11,900
+6,400
+116% +$247K ﹤0.01% 2188
2020
Q2 		$246K Buy
+5,500
New +$233K ﹤0.01% 2337

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM's RLMD Position: Q4 2022 in Review

UBS AM sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 22,671 shares — an estimated $839K sold.

UBS AM first reported a position in RLMD in Q2 2020 and held it in 8 quarters. The position peaked at $839K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • UBS AM reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • UBS AM sold 22,671 Relmada Therapeutics shares in Q4 2022, an estimated $839K.
  • UBS AM first reported a position in Relmada Therapeutics in Q2 2020 and held it in 8 quarters.
  • UBS AM's Relmada Therapeutics position peaked at $839K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.